Related Experiment Video
Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Myocardial Revascularization Trials
Marc Ruel1, Volkmar Falk2, Michael E Farkouh3
1University of Ottawa Heart Institute, University of Ottawa, Canada (M.R., D.G.).
Insights
Recent trials comparing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main disease may overstate PCI's benefits. Careful interpretation of evidence and improved trial design are recommended for future studies.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Cardiac Surgery
Background:
- Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are primary revascularization strategies for left main and multivessel coronary artery disease.
- Recent trials have compared the efficacy and safety of PCI versus CABG, yielding complex and sometimes debated results.
Purpose of the Study:
- To critically review the evidence from recent myocardial revascularization trials comparing PCI and CABG.
- To analyze potential biases in trial design, patient selection, and endpoint selection that may influence the interpretation of results.
- To provide recommendations for the cautious interpretation of current evidence and the design of future clinical trials.
Main Methods:
- Systematic review and critical appraisal of published data from major randomized controlled trials.
- Analysis of trial methodologies, including patient inclusion/exclusion criteria and outcome definitions.
- Synthesis of evidence to evaluate the comparative effectiveness of PCI and CABG in specific patient subgroups.
Main Results:
- The claimed noninferiority of PCI in certain patient groups (e.g., non-diabetic, low anatomic complexity) may be influenced by trial design.
- Patient selection favoring suitability for PCI and endpoint optimization potentially skewed results favoring PCI over CABG.
- Evidence suggests CABG may still offer superior long-term outcomes in specific complex patient populations.
Conclusions:
- A circumspect interpretation of current evidence comparing PCI and CABG is warranted.
- Future trials should prioritize robust design, unbiased patient selection, and appropriate endpoints to accurately reflect comparative effectiveness.
- Collaborative efforts in trial design and conduct are essential for advancing knowledge in cardiovascular interventions.
Abstract:
This article reviews the context and evidence of recent myocardial revascularization trials that compared percutaneous coronary intervention with coronary artery bypass grafting for the treatment of left main and multivessel coronary artery disease. We develop the rationale that some of the knowledge synthesis resulting from these trials, particularly with regard to the claimed noninferiority of percutaneous coronary intervention beyond nondiabetic patients with low anatomic complexity, may have been affected by trial design, patient selection based on suitability for percutaneous coronary intervention, and end point optimization favoring percutaneous coronary intervention over coronary artery bypass grafting. We provide recommendations that include holding a circumspect interpretation of the currently available evidence, as well as suggestions for the collaborative design and conduct of future clinical trials in this and other fields.
Related Concept Videos
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Statistical Software for Data Analysis and Clinical Trials
Stereotypes, Prejudice, and Discrimination
Uncertainty in Measurement: Accuracy and Precision

